decisionhealth Newsletters, Part B News - 2024 Issue 10 (October)
Part B drug rebate program sails on with 54 total drugs in Q3
Subscribe or sign in to view the full article.
Article Overview
This article covers the quarterly update to the Medicare Prescription Drug Inflation Rebate Program for Part B drugs, including the latest list size, the program’s federal policy context, and examples of how beneficiary cost-sharing is affected. It is relevant to Medicare billing and reimbursement professionals, pharmacy and healthcare financial staff, and coders who follow CMS and HHS drug payment guidance. The article also points to official HHS and CMS resources that summarize the current quarter’s rebated drugs and related coinsurance changes.
Why This Topic Matters
Quarterly rebate updates can affect Medicare Part B patient cost-sharing and payment planning for drugs covered under the program. Staying current with HHS and CMS announcements helps organizations monitor policy-driven changes tied to inflation-based rebates.
What You Will Learn
- How the Medicare Prescription Drug Inflation Rebate Program is being updated on a quarterly basis
- What the current Part B rebate announcement is generally about
- How official HHS and CMS publications support tracking of the latest rebate list and coinsurance changes
- Which types of stakeholders may need to monitor these updates
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle professionals
- Pharmacy billing specialists
- Compliance staff
- Healthcare finance staff
- Medicare reimbursement analysts
Codes Discussed
Subscribe or sign in to view the full article.


Quick, Current, Complete - www.findacode.com